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SUMMARY
Polycomb proteins are classical regulators of stem
cell self-renewal and cell lineage commitment and
are frequently deregulated in cancer. Here, we find
that the non-canonical PRC1.1 complex, as identified
by mass-spectrometry-based proteomics, is criti-
cally important for human leukemic stem cells.
Downmodulation of PRC1.1 complex members, like
the DNA-binding subunit KDM2B, strongly reduces
cell proliferation in vitro and delays or even abro-
gates leukemogenesis in vivo in humanized xeno-
graft models. PRC1.1 components are significantly
overexpressed in primary AML CD34+ cells. Besides
a set of genes that is targeted by PRC1 and PRC2,
ChIP-seq studies show that PRC1.1 also binds a
distinct set of genes that are devoid of H3K27me3,
suggesting a gene-regulatory role independent of
PRC2. This set encompasses genes involved in
metabolism, which have transcriptionally active
chromatin profiles. These data indicate that PRC1.1
controls specific genes involved in unique cell bio-
logical processes required for leukemic cell viability.
INTRODUCTION
Stem cell self-renewal and lineage specification are tightly regu-
lated processes that are of vital importance for proper embryonic
development and maintenance of somatic stem cells in adults.
The Polycomb group protein family of epigenetic modifiers is
critically involved in the regulation of stem cell self-renewal and
differentiation.
In general, Polycomb proteins reside in two complexes: the
Polycomb repressive complex 1 (PRC1) and 2 (PRC2) (Simon
and Kingston, 2013). The PRC2 complex, consisting of the
core components EED, SUZ12, and EZH1 or EZH2, can trime-
thylate lysine 27 on histone H3 (H3K27me3) via EZH1 or EZH2
(Cao et al., 2002; Ezhkova et al., 2011; Kirmizis et al., 2004; Kuz-
michev et al., 2002; Shen et al., 2008). The PRC1 complex has
five subunits (PCGF, PHC, CBX, SCM, and RING1) and displays
RING1-mediated ubiquitination activity toward histone H2A at
lysine 119 (H2AK119ub) (Buchwald et al., 2006; de Napoles
et al., 2004; Levine et al., 2002; Wang et al., 2004). The human
genome encodes for multiple paralogs for each of the PRC1 sub-
units: six PCGF members (PCGF1, PCGF2, PCGF3, PCGF4,
PCGF5, and PCGF6), three PHC members (PHC1, PHC2, and
PHC3), five CBX members (CBX2, CBX4, CBX6, CBX7, and
CBX8), three SCM members (SCML1, SCML2, and SCMH1),
and two RING1 members (RING1A and RING1B). Accumulating
evidence suggests that PRC1 paralogs reside in the complex in a
mutually exclusive manner, allowing a so-far poorly understood
complexity of regulation by PRC1 (Gao et al., 2012; Maertens
et al., 2009; Morey et al., 2012; van den Boom et al., 2013; Van-
damme et al., 2011).
The classical view on Polycomb-mediated silencing is a
consecutive model where PRC2 first trimethylates H3K27 fol-
lowed by CBX-dependent binding of PRC1 to H3K27me3 and
subsequent ubiquitination of H2AK119 (Cao et al., 2002; Bern-
stein et al., 2006; Kaustov et al., 2011). In line with this model,
genome-wide chromatin binding studies showed frequent co-
occupancy of PRC1 and PRC2 at Polycomb target genes in
mammalian cells (Boyer et al., 2006; Bracken et al., 2006; Lee
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Figure 1. Primary MLL-AF9 Leukemic Cells Critically Depend on PRC1.1
(A) Schematic overview of a Polycomb shRNA screen in primary MLL-AF9 (MA9)-transformed CB cells.
(B) Cumulative cell growth of MA9 cells in a sorted liquid culture expressing indicated Polycomb shRNAs.
(legend continued on next page)
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et al., 2006). PRC1 complexes containing a CBX subunit and
PCGF2 (MEL18) or PCGF4 (BMI1) are referred to as canonical
PRC1 complexes (PRC1.2/PRC1.4) and often co-occupy target
loci (Gao et al., 2012). However, recent work from various groups
led to the identification of a class of non-canonical PRC1 com-
plexes that contain RYBP but lack a CBX subunit and are tar-
geted to chromatin independently of H3K27me3 (Morey et al.,
2013; Tavares et al., 2012). In addition, other non-canonical
PRC1 complexes were identified that are targeted to chromatin
by KDM2B (PRC1.1) or L3MBTL2 (PRC1.6), the first being a
DNA-binding protein that specifically targets non-methylated
CpG islands via its CxxC domain (Gearhart et al., 2006; Farcas
et al., 2012; He et al., 2013; Wu et al., 2013; van den Boom
et al., 2013; Gao et al., 2012; Qin et al., 2012). Recent publica-
tions have shown that the H2AK119ub mark itself can also
independently recruit the PRC2 complex (Cooper et al., 2014;
Blackledge et al., 2014; Kalb et al., 2014). In this latter scenario,
the ubiquitination of H2AK119 is dependent on non-canonical
PRC1 complexes.
Self-renewal of hematopoietic stem cells (HSCs) critically
depends on Polycomb protein function. Homozygous deletion
of Bmi1, encoding PCGF4 (BMI1), resulted in reduced numbers
of hematopoietic progenitors and more differentiated cells,
eventually leading to hematopoietic failure (van der Lugt
et al., 1994). Other studies showed that BMI1 has a central reg-
ulatory role in self-renewal of HSCs by inducing symmetric cell
division(s) both in mouse and human model systems (Iwama
et al., 2004; Lessard and Sauvageau, 2003; Park et al., 2003;
Rizo et al., 2008, 2009). Using an small hairpin RNA (shRNA)
screen in human hematopoietic cells, we recently showed
that many PRC1 paralog family members lack functional
redundancy, suggesting that multiple PRC1 complexes exist
that locate to specific target genes (van den Boom et al.,
2013). In addition, murine hematopoietic cells display differen-
tiation stage-specific expression of CBX paralogs, and a leuke-
mogenic role for CBX7 has been suggested (Klauke et al.,
2013). Similarly, PRC1 complex composition changes upon
differentiation of mouse embryonic stem (mES) cells. Whereas
CBX7-PRC1 is present in self-renewing mES cells and impor-
tant for pluripotency, CBX7 expression is lost upon mES cell
differentiation. Instead, CBX2-, CBX4- and CBX8-containing
PRC1 complexes appear to regulate lineage specification
(Morey et al., 2012; O’Loghlen et al., 2012). Furthermore,
Morey et al. showed that PCGF2-PRC1 is required for cardiac
differentiation of mES cells and that exchange of subunits en-
ables gene repressive and activating functions of the complex
that are specific for the differentiation stage (Morey et al.,
2015).
Here, we investigated PRC1 paralog dependency in human
acute myeloid leukemia (AML). Using an shRNA strategy in a
human lentiviral MLL-AF9 leukemia model and in primary AML
patient cells combined with proteome analysis, we identify the
non-canonical PRC1.1 complex as an essential epigenetic regu-
lator in leukemic cells in vitro and in vivo. Chromatin immunopre-
cipitation sequencing (ChIP-seq) analyses in K562 cells and
primary CD34+ AML patient cells show that PRC1.1 binds a
unique set of active genes independent of PRC2. Gene Ontology
(GO) analyses of these targets reveal enrichment for genes
involved in metabolism and cell-cycle regulation. Our data
show that the non-canonical PRC1.1 complex is essential for
leukemic stem cells and that inhibition of this complex may be
beneficial for the treatment of AML.
RESULTS
Essential Role for Non-canonical PRC1.1 in Leukemic
Cells
To characterize the requirement of PRC1 paralog family mem-
bers for leukemic cell viability we performed an shRNA-mediated
knockdown screen in our MLL-AF9 leukemic human model sys-
tem (Horton et al., 2013). Cord blood (CB) CD34+ cells were
transduced with MLL-AF9 and subsequently allowed to trans-
form along the myeloid lineage over the course of 3–4 weeks
(Figure 1A). CB MLL-AF9 (MA9)-transformed cells were subse-
quently transducedwith pLKO.1 shRNA vectors directed against
various PRC1 paralog family members. Knockdown efficiencies
of shRNAs are displayed in Figure S1A. Phenotypes were evalu-
ated in vitro followed by more detailed in vitro and in vivo ana-
lyses of selected candidates (Figure 1A). Most PRC1 paralog
knockdowns displayed a mild negative effect on cumulative
cell growth in sorted myeloid liquid cultures in two independent
experiments (Figures 1B and S1B). However, a strongly reduced
proliferation was observed upon knockdown of PCGF1, PCGF2,
RING1A, and RING1B, which was also reflected by colony-form-
ing cell (CFC) analyses where a sharp decrease of progenitor fre-
quencies was observed (Figure 1C). We noted that CBX7 knock-
down resulted in moderate phenotypes in liquid cultures while
strong phenotypes were observed in CFC assays, suggesting
that CBX7 is relevant for cells capable of colony formation in
methylcellulose but less so for cells that sustain long-term liquid
cultures. Next, we focused on the two members of the RING1
paralog family: the E3 ubiquitin ligases RING1A and RING1B.
Annexin V staining revealed that both RING1A and RING1B
knockdown induced apoptosis in both CB MA9 cells and K562
leukemic cells (Figures S1C and S1D) as well as in several other
leukemic cell lines (data not shown). SinceMLL-AF9 can give rise
(C) CFC analysis of Polycomb knockdown CB MA9 cells. Error bars represent SD.
(D) MS5 stromal co-cultures of CB MA9 cells expressing SCR, RING1A, or RING1B #1 shRNAs grown under lymphoid- and myeloid-permissive conditions.
Arrows indicate time of replating.
(E) Canonical and non-canonical PRC1 complex members identified by LC-MS/MS in Avi-RING1A, Avi-RING1B, Avi-PCGF1, Avi-PCGF2, Avi-PCGF4, and
CBX2-Avi pullouts from K562 cells. Total spectrum counts per protein corrected for expected peptides are shown.
(F) Schematic model showing that RING1A and RING1B reside in both the canonical PRC1 complex and the non-canonical PRC1.1 complex.
(G) Relative fraction of GFP+mCh+ cells in unsorted myeloid-permissive liquid cultures of CB MA9 cells expressing SCR, PCGF1, PCGF2, PCGF4, RING1B,
BCOR, and KDM2B shRNAs. Error bars represent SD.
(H) Relative fraction of GFP+mCh+ CB MA9 cells as in panel G expressing SCR, PCGF1, PCGF4, RYBP, CBX2 and KDM2B shRNAs. Error bars represent SD.
(I) CFC analysis of CB MA9 cells expressing SCR, RING1B, BCOR or KDM2B shRNAs. Error bars represent SD.
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to both myeloid leukemia (AML) and lymphoid leukemia (acute
lymphoblastic leukemia [ALL]), in particular in pediatric patients,
we tested whether CBMA9 cells grown under lymphoid-permis-
sive conditions were also sensitive to RING1A or RING1B knock-
down. CB CD34+ cells were co-transduced with MLL-AF9 (GFP)
and pLKO.1 mCherry (mCh) shRNA vectors, and unsorted MS5-
driven bone marrow (BM) stromal cocultures under myeloid- or
lymphoid-permissive conditions were initiated (Figure 1D).
Next, the percentage of GFP+mCh+ cells within the total fraction
of GFP+ cells was measured over the course of the experiment.
While in the MA9/shSCR control group the GFP+mCh+ fraction
was relatively stable, it was rapidly reduced in the MA9/
shRING1A and MA9/shRING1B groups, both under myeloid-
and lymphoid-permissive conditions, suggesting that RING1A
and RING1B are essential for transformation and maintenance
of both myeloid and lymphoid MLL-AF9-driven leukemias.
To investigate the molecular background of RING1A and
RING1B function, we identified the interactome of RING1A,
RING1B, PCGF1, PCGF2, PCGF4, and CBX2. K562 cells were
transduced with vectors expressing a bicistronic transcript en-
coding Avi-fusion proteins and the biotin ligase BirA fused to
GFP and streptavidin-mediated pull outs were performed fol-
lowed by LC-MS/MS analyses (Table S1) (van den Boom et al.,
2013). Figure 1E shows a summary of the interactomes of these
proteins, where we focused on known canonical and non-ca-
nonical PRC1 complexes. Since the total number of potentially
identifiable peptides after trypsin digestion obviously differs be-
tween proteins, total spectra counts were corrected for ex-
pected peptides based on in silico protein digests. RING1A
and RING1B both co-purified many proteins that reside in ca-
nonical PRC1 complexes (PRC1.2 and PRC1.4) such as PHC,
CBX, and SCML proteins (Figure 1E). In RING1B pullouts,
RING1A was not detected, and in RING1A pullouts, only little
RING1B was identified, in line with earlier data from our lab
and others showing that RING1A and RING1B are mutually
exclusive in PRC1 complexes (Maertens et al., 2009; van den
Boom et al., 2013). Interestingly, we found that the non-canoni-
cal PRC1.1 complex specifically co-purified with RING1A,
RING1B, and PCGF1 (Figure 1E), but not with PCGF2, PCGF4,
and CBX2. This led us to speculate that the phenotypic conse-
quence of RING1A, RING1B, and PCGF1 knockdown in MLL-
AF9 leukemic cells might be a consequence of compromised
PRC1.1 complex activity (Figure 1F). To more specifically
address the role of the PRC1.1 complex in leukemia, we gener-
ated shRNAs directed against the PRC1.1 subunits KDM2B and
BCOR (knockdown efficiencies are shown in Figure S1A). CB
MA9 cells were transduced with SCR, PCGF1, PCGF2,
PCGF4, RING1B, BCOR, or KDM2B shRNAs, all with multiple in-
dependent shRNAs, and liquid cultures were initiated. Clearly,
knockdown of KDM2B, BCOR, PCGF1, and RING1B induced a
quick loss of the GFP+mCh+ fraction, whereas PCGF2 and
PCGF4 knockdown showed a milder, though still negative
phenotype (Figure 1G). Next, unsorted CB MA9 cultures were
performed using two independent shRNAs directed against
RYBP (a common component in various non-canonical PRC1
complexes; Gao et al., 2012; Garcı´a et al., 1999; Morey et al.,
2013; Tavares et al., 2012), and we compared those with
PCGF1, PCGF4, CBX2, and KDM2B knockdowns (Figure 1H).
Interestingly, despite high knockdown efficiencies for both
RYBP hairpins (Figure S1A), RYBP depletion resulted in a mild
negative phenotype less severe than seen upon PCGF1 and
KDM2B knockdowns. Finally, RING1B, BCOR, and KDM2B
downmodulation also impaired the MLL-AF9 CFC frequency
(Figure 1I). Taken together, these data show that the non-canon-
ical PRC1.1 complex is pivotal for leukemic cell survival in vitro.
PRC1.1 Is Essential for MLL-AF9-Induced
Leukemogenesis In Vivo
Next, we investigated Polycomb-dependency of leukemic cells
in vivo. CB CD34+ cells were co-transduced with MLL-AF9 and
SCR, RING1A, or RING1B shRNA vectors (Figure 2A). Next,
GFP+mCh+ cells were sorted (Figure 2B), and 1 3 105 cells
were injected intravenously per mouse. Peripheral blood chime-
rism levels of GFP+mCh+ cells were monitored by regular blood
sample analysis andmicewere sacrificedwhen chimerism levels
in the blood exceeded 30%. BM, spleen, and liver analyses of
sacrificed mice showed that all three organs displayed high
levels of chimerism (>90%), indicative of a full-blown leukemia
(Figure S2A). Leukemia development was first observed in the
MA9/shSCR group. Downregulation of RING1A significantly de-
layed leukemia development, while knockdown of RING1B
completely prevented MA9-induced leukemic transformation
in vivo within the time frame of the experiment (Figures 2C and
2D). Spleen weights in MA9/shSCR leukemic mice were strongly
increased compared to non-leukemic mice (Figure 2E). Despite
the absence of leukemia development, MA9/shRING1B mice
recurrently showed low but clearly detectable chimerism levels,
which slowly increased over time (Figure 2C). Some mice trans-
planted with MA9/shRING1A cells did develop leukemia, but
qRT-PCR analysis of BM cells from these leukemicmice showed
Figure 2. PRC1.1 Depletion Interferes with MLL-AF9 Leukemogenesis In Vivo
(A) Schematic overview of shRNA expression in a primary MLL-AF9 (MA9) xenograft model.
(B) FACS sort of MA9 (GFP) and shRNA (mCh) expressing cells at the day of injection.
(C) Peripheral blood chimerism of MA9/shSCR, MA9/shRING1A, or MA9/shRING1B cells over the course of the experiment.
(D) Kaplan-Meier survival plot of mice intravenously injected with MA9 shSCR, shRING1A, or shRING1B expressing cells (n = 4 per group). This survival plot is a
representative example from two independent experiments. Statistical analysis was performed using a log-rank test.
(E) Spleen weights of leukemic mice (black symbols) at the day of sacrifice or non-leukemic mice (red symbols) at the end of the experiment.
(F) Average knockdown efficiencies of RING1A in bone marrow of leukemic mice. Error bars represent SEM.
(G) Peripheral blood chimerism of MA9/shSCR and MA9/shKDM2B cells over the course of the experiment.
(H) Kaplan-Meier survival plot of mice intravenously injected with MA9/shSCR or MA9/shKDM2B expressing cells (n = 5 per group). Statistical analysis was
performed using a log-rank test.
(I) FACS plots showing BM analyses at the day of sacrifice of MA9/shSCR and MA9/shKDM2B mice.
(J) Average KDM2B knockdown efficiencies in bone marrow of SCR mice (n = 5) and two individual KDM2B knockdown mice.
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that the reduction of RING1A mRNA expression levels was
considerably less compared to knockdown efficiencies directly
after transduction (Figure 2F). These data suggest that only
clones with a relatively mild RING1A knockdown can persist,
while clones with a strong RING1A knockdown do not expand
or only slowly expand in vivo. In accordance with previous
studies (Horton et al., 2013), leukemic mice mostly developed
CD19+ lymphoid leukemias (ALL), and small co-existing
CD33+/CD19 myeloid clones were observed only in some
mice (Figure S2B).
Next, we selectively interfered with non-canonical PRC1.1
function by knocking down KDM2B. Here, an MLL-AF9 second-
ary transplantation model was used where leukemic cells were
harvested from mice that developed a full-blown lymphoid
leukemia after transplantation of MA9-transduced CD34+ CB
cells. Subsequently, these cells were transduced with
SCR and KDM2B shRNA vectors, GFP+mCh+ cells were sorted
and 5 3 105 cells were intravenously injected per mouse
(n = 5). Peripheral blood analyses showed that MA9/shSCR
mice quickly developed high chimerism levels, whereas MA9/
shKDM2B mice displayed a slower increase in chimerism and
sometimes lost chimerism at later stages of the experiment (Fig-
ure 2G). Survival analysis showed that MA9/shKDM2B mice
have a significantly delayed onset of leukemia compared
to MA9/shSCR controls (Figure 2H). Importantly, the MA9/
shKDM2B mice that did develop leukemia either only showed
chimerism of single GFP+ MA9 cells (Figure 2I; likely due to
sort impurities) or did not show knockdown of KDM2B (Figure 2J;
KDM2B-3 and KDM2B-4).
Altered Expression of Polycomb Proteins in AML
Given that the PRC1.1 complex was of vital importance for
leukemic cells, we hypothesized that the expression of its com-
ponents might be deregulated in primary leukemic patient sam-
ples. Previously, we performed transcriptome studies in AML
CD34+ cells (n = 60) and normal BM CD34+ cells (n = 40) (de
Jonge et al., 2011). Here, we investigated which PRC2, PRC1,
or PRC1.1 complex partners were significantly differentially ex-
pressed between AML CD34+ and normal BM CD34+ cells.
Among others, the PRC1.1 components BCOR, PCGF1, and
RING1A were significantly upregulated in AML CD34+ cells (Fig-
ure S2C; Table S2). Similarly, HemaExplorer datasets (http://
servers.binf.ku.dk/hemaexplorer/) also showed that PRC1.1
members were significantly upregulated compared to normal
HSC/progenitor fractions (Figure S2D; Table S2). In contrast,
the expression of PRC2 complex members EZH2 and EED
was significantly lower in AML CD34+ cells, whereas EZH1
showed increased expression.
PRC1.1 Is Required for Primary Patient AMLCell Growth
In Vitro and In Vivo
Given that the PRC1.1 complex was essential for MLL-AF9-
transformed cells and its expression was increased in primary
AML patient cells, we investigated the functional requirement
of PRC1.1 in primary samples (patient details are provided in Ta-
ble S2). Primary AML patient CD34+ cells were transduced with
SCR, RING1A, RING1B, or KDM2B shRNAs, and unsorted MS5
stromal co-cultures were initiated (Figures 3A and S3A). Knock-
down of KDM2B led to a quick loss of mCh+ cells over time
compared to SCR control cultures, whereas shRING1B-ex-
pressing cells were lost as well but at lower rates (Figure 3B).
Next, we performed co-cultures using CD34+ AML cells (two pa-
tients) transduced with SCR, PCGF1, PCGF2, PCGF4, RING1A,
RING1B, BCOR, or KDM2B shRNAs (Figures 3B and S3B). In
both AMLs, mCh+ cells were quickly lost upon knockdown of
PRC1.1 components like KDM2B, BCOR, PCGF1, or RING1B.
Slightly milder phenotypes were observed upon depletion of
PCGF2, PCGF4, or RING1A. Together, these data suggest that
although there is some heterogeneity between individual AML
patients, the non-canonical PRC1.1 complex is critically impor-
tant in AML.
Next, we tested the effect of RING1A, RING1B, or KDM2B
knockdown on AML development in vivo using a humanized
model that is based on subcutaneous implantation of human
BM-like scaffolds as reported previously (Groen et al., 2012;
Gutierrez et al., 2014; P. Sontakke and J.J.S., unpublished
data). Shortly, four hybrid scaffolds consisting of three 2 to
3 mm biphasic calcium phosphate (BCP) particles loaded
with human mesenchymal stromal cells (MSCs) were implanted
subcutaneously into NSG mice, where they formed bone and
differentiated into bone marrow stromal cells, together serving
as a human niche for AML leukemic stem cells. Six weeks after
implantation the scaffolds were well vascularized and scaffold 1
and 3 were injected with 200,000 mCh+ AML cells (AML 8) ex-
pressing SCR, RING1A, RING1B, or KDM2B shRNAs (Fig-
ure 3C). Clearly, whereas all mice injected with shSCR cells
developed leukemia after 100–130 days, only one shRING1B
mouse developed leukemia, but with severely delayed onset
(day 188). The other shRING1B and shKDM2B mice did not
develop tumors (Figure 3D). One shRING1A mouse developed
leukemia, but also with longer latency compared to SCR con-
trol mice. At day 200 after intra-scaffold injection, all remaining
mice were sacrificed and no signs of tumor initiation were
observed (Figure 3E). Taken together, these data suggest that
PRC1.1 is functionally relevant across a broad set of AML
subtypes.
PRC1.1 Targets Active Genes Independent of
H3K27me3
Next, we performed ChIP-seq studies to identify non-canonical
PRC1.1 and canonical PRC1 target genes in leukemic cells.
For this purpose, we expressed GFP fusions of RING1A,
RING1B, PCGF1, PCGF2, PCGF4, and CBX2 or non-fused
GFP in K562 leukemic cells and performed ChIP reactions using
an a-GFP antibody. We carefully analyzed the expression levels
of GFP-fusion proteins compared to endogenous protein
expression. Fluorescence-activated cell sorting (FACS) analyses
showed that all cell lines displayed comparable mean fluores-
cence intensities of GFP (Figure S4A), and western blot analyses
showed that GFP-fusion proteins were expressed at levels com-
parable to their endogenous counterparts (Figure S4B). Further-
more, we compared our GFP-CBX2 and GFP-RING1B tracks
with endogenous CBX2 and RING1B ChIP-seq datasets in
K562 cells from ENCODE/Broad, which showed strong overlap
in target genes, suggesting that the GFP moiety did not interfere
with chromatin targeting of the proteins (Figures S4C and S4D).
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Figure 3. PRC1.1 Is Required for In Vitro Growth of Primary AML Patient Cells and Leukemogenesis In Vivo
(A) Relative fraction mCh+ cells of primary AML patient cells from four independent patients transduced with SCR, RING1A, RING1B, or KDM2B knockdown
vectors grown on a stromal cell layer.
(B) Relative fractionmCh+ cells as in (A), where primary AML patient cells from two independent patients were transduced with SCR andmultiple PCGF1, PCGF2,
PCGF4, RING1A, RING1B, BCOR, and KDM2B shRNAs.
(C) Experimental setup of our humanized niche scaffold xenograft model using primary AML patient cells transduced with pLKO.1 mCherry SCR, RING1A,
RING1B, or KDM2B shRNA vectors.
(D) Kaplan-Meier survival plot of mice intra-scaffold injected with AML 8 CD34+ cells expressing SCR (n = 3), RING1A (n = 2), RING1B (n = 3), or KDM2B (n = 2)
shRNAs. Statistical analysis was performed using a log-rank test.
(E) Pictures from skin of sacrificed mice showing vascularized scaffolds and tumors in shSCR, shRING1A, and shRING1B mice.
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In addition, we also generated H3K27me3 and H2AK119ub
profiles in K562 cells. Peak calling was performed, and normal-
ized read counts were calculated for each precipitated compo-
nent at each called chromosomal position. Subsequently, we
identified PRC1.1 binding sites (PCGF1+, RING1B+, and
CBX2), PRC1 binding sites (RING1B+, CBX2+, and PCGF1),
and genomic regions containing both PRC1.1 and PRC1
(PCGF1+, RING1B+, and CBX2+; Figure 4A; Table S4). RING1A
and RING1B binding sites showed a near to complete overlap
(Figure 4B). Supervised clustering analysis was performed on
PRC1.1 and/or PRC1 occupied loci, and heatmaps and density
plots are shown in Figures 4C and S5A. Interestingly, and in
contrast to PRC1, PRC1.1 binding sites were completely devoid
of H3K27me3. H2AK119ub was enriched in all clusters, although
distinct patterns could be observed. In addition, we performed
ChIP-seq analyses using an antibody recognizing endogenous
KDM2B (Figure 4C). Clearly, KDM2B was enriched at genomic
loci assigned as PRC1.1 and ‘‘both’’ loci, but not PRC1 loci, sup-
porting our annotation of PRC1.1 targets. Comparison of
PCGF1, PCGF2, and PCGF4 showed that whereas PRC1 target
genes were devoid of PCGF1, PRC1.1 target genes also showed
some occupancy of PCGF2 and PCGF4 suggesting that PRC1.1
loci may, to some extent, also be co-occupied by canonical
PRC1 (Figure S5B).
Genome-wide analysis of PRC1.1 and PRC1 peaks showed
that PRC1.1 was mainly targeted to transcription start sites
(TSSs) whereas themajority of PRC1 peakswere located in inter-
genic or intronic regions (Figures 4D and S5C; Table S4). Chro-
mosomal regions harboring both PRC1 and PRC1.1 complexes
generally located to TSSs or intergenic regions. In agreement
with previously published data showing KDM2B-dependent
PRC1.1 targeting to non-methylated CpG islands (CGIs) we
observed preferential binding of PRC1.1 to CGIs (94.1%, Fig-
ure 4E) (Farcas et al., 2012; He et al., 2013; Wu et al., 2013). In
contrast, PRC1 peaks did not enrich at CGIs (18.2%), and peaks
targeted by both PRC1 and PRC1.1 showed intermediate
enrichment for CGIs (68.9%). Genes were assigned as being
regulated by PRC1.1, PRC1, or both when a peak was
called within a 5 to +5 kb region relative to a TSS
(GREAT; http://bejerano.stanford.edu/great/public/html/; Table
S4; McLean et al., 2010). Thus, 2,434 PRC1.1 target genes
were identified, 386 genes targeted by PRC1 and 1029 genes
bound by both complexes. Representative examples of ChIP-
seq profiles of PRC1.1, PRC1, and both target genes are
displayed in Figure 4F. Specific comparison of these genes
with our H3K27me3 and H2AK119ub ChIP-seq tracks and
ENCODE/Broad K562 H3K4me3 profiles showed strong enrich-
ment for H2AK119ub and H3K4me3 but not H3K27me3 at
PRC1.1 loci, whereas PRC1 target genes were enriched for
H3K27me3, H2AK119ub, and, to a lesser extent, H3K4me3 (Fig-
ure 4G). Since PRC1.1 target genes were strongly enriched
for the active chromatin mark H3K4me3 and devoid of
H3K27me3, we hypothesized that PRC1.1 target genes may
be actively transcribed in contrast to PRC1 target genes that
are typically repressed. To investigate this, available K562 tracks
(ENCODE/Broad) for H3K36me3, which enriches at actively tran-
scribed genes throughout the gene body, and serine 5 phos-
phorylated active RNA polymerase II (RNAPII S5P) were
analyzed. Both H3K36me3 and RNAPII S5P were strongly en-
riched at PRC1.1 target genes, whereas only weak enrichment
was observed at PRC1 target genes (Figures S5D and S5E).
GO analyses strikingly showed that PRC1.1 targeted genes
involved in metabolism, whereas PRC1-bound genes were en-
riched for classical Polycomb-associated GO terms related to
development and lineage specification (Figure 4H). Genes that
were targeted by both PRC1 and PRC1.1 showed the strongest
enrichment for developmental GO terms. Specific analyses for
KEGG pathway-associated terms indicated that leukemia-asso-
ciated pathways were enriched in the PRC1.1 as well as the
‘‘both’’ category of target genes.
Independent ChIP-qPCR experiments confirmed our ChIP-
seq data and examples of ChIP-seq screenshots and ChIP-
qPCRs are shown in Figures S6A and S6B. Strong binding of
PCGF1, RING1A, and RING1B, but not PCGF2 or PCGF4, was
observed around the TSSs of PRC1.1 targets LIMD2, GATA5,
MYC, and PKM. These loci were also enriched for H2AK119ub
and H3K4me3 marks but devoid of H3K27me3 marks. Interest-
ingly, downmodulation of RING1A or RING1B resulted in a signif-
icant decrease in MYC expression, indicating that this locus is
not repressed but likely activated by PRC1.1 (Figure S6C). In
contrast, the CDKN1A locus was targeted by both canonical
PRC1 and non-canonical PRC1.1 (Figures S6A and S6B) and
knockdown of RING1A/B resulted in a significant increase in
p21 expression, showing Polycomb repression of this locus (Fig-
ure S6C). Taken together, these data show that PRC1.1 regu-
lates active genes involved in metabolism and cell cycle that
are devoid of PRC2 activity.
Identification of Non-canonical PRC1.1 Targets in
Primary AML Patient Cells
Next, we identified PRC1.1 target genes in primary CD34+ AML
cells derived from six independent AML patients (patient details
are provided in Table S3). ChIP-seq was performed using
antibodies recognizing endogenous KDM2B, H2AK119ub,
Figure 4. Non-canonical PRC1.1 and PRC1 Target Unique Sets of Genes Involved in Specific Pathways
(A) Venn diagram showing overlap of RING1B, PCGF1, and CBX2 called peaks.
(B) Venn diagram displaying overlap of RING1A and RING1B called peaks.
(C) ChIP-seq heatmap of peaks and surrounding regions (5 to +5 kb) targeted by PRC1.1 (n = 3,327), PRC1 (n = 4,016), or both (n = 2,122).
(D) Localization analysis of identified PRC1.1, PRC1, and ‘‘both’’ peaks across the genome. TSS, transcription stat site; CGI, CpG island.
(E) Percentage of peaks targeted by PRC1.1, PRC1, or both that are localized to CGIs.
(F) Characteristic examples of genes targeted by PRC1.1, PRC1, or both complexes at the transcription start site (TSS).
(G) Percentage of genes targeted by PRC1.1, PRC1, or both based on occupancy in a5 kb to +5 kb window surrounding the TSS, which enrich for H3K27me3,
H2AK119ub, or H3K4me3.
(H) Gene Ontology (GO) analysis of genes targeted by PRC1.1, PRC1, or both.
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H3K27me3, and H3K4me3. Subsequently, three categories of
target genes were defined: PRC1.1 (KDM2B+, H2AK119ub+,
and H3K27me3), PRC1 (KDM2B, H2AK119ub+, and
H3K27me3+), or genes targeted by both complexes that were
positive for all three marks (Figure 5A; Table S4). Heatmaps of
all annotated peak regions (5 to +5 kb) in all AMLs are shown
in Figure 5B. Similar to K562 cells, genome-wide peak localiza-
tion analyses showed that PRC1.1 preferentially localized to
CGI-containing TSSs, whereas the majority of PRC1 bound
loci localized to intergenic regions (Figure 5C). Furthermore,
PRC1.1 peaks were strongly enriched for H3K4me3 (90%)
across all AML samples, whereas PRC1-specific targets showed
a much lower number of peaks with H3K4me3 (30%; Figures
5B and 5D). Genomic regions targeted by both PRC1 and
PRC1.1 were also highly enriched for H3K4me3 (98%). Fig-
ure 5E shows examples of ChIP-seq profiles of PRC1.1, PRC1,
or both target genes. Similar to K562 cells, PRC1.1 was found
to target the MYC and PKM genes whereas CDKN1A was tar-
geted by both PRC1.1 and PRC1. Next, we performed indepen-
dent ChIP-qPCR experiments on AML2 and AML3 and analyzed
H3K27me3, H2AK119ub, H3K4me3, KDM2B, and PCGF4 occu-
pancy at PRC1.1, PRC1, and both loci (Figure 6A). Similar to our
ChIP-seq data, we observed that PRC1.1 targets were enriched
for H2AK119ub, H3K4me3, and KDM2B, but not H3K27me3. In
contrast, PRC1 targets showed high levels of H3K27me3 and
H2AK119ub but low levels of H3K4me3 and KDM2B. Genes tar-
geted by both complexes were enriched for H3K27me3,
H2AK119ub, H3K4me3, and KDM2B. PCGF4 showed the stron-
gest enrichment at PRC1 target genes but was also observed at
some PRC1.1 target genes. GO analyses showed that PRC1.1
target genes were enriched for metabolic processes, chromatin
organization, and cell cycle, whereas the PRC1-specific and
both targets were highly enriched for developmental GO terms
(Figure 6B; Table S5). Finally, we also performed ChIP-seq anal-
ysis on CD34+ cells derived from mobilized peripheral blood (PB
CD34+). PRC1.1, PRC1, and both target genes were annotated
in this sample (Figure 6C), and we tested the overlap of
PRC1.1 target genes between the AML samples and control
PB (Figure 6D). Thus, common PRC1.1 targets were identified,
as were targets that were specific for either AML CD34+ cells
or PB CD34+ cells (Figure 6D; Table S6).
DISCUSSION
Our data provided here demonstrate that leukemic cells from
AMLpatients are critically dependent on a functional non-canon-
ical PRC1.1 complex. Proteomics studies in leukemic cells re-
vealed strong interactions between the RING1A/B ubiquitin
ligases and non-canonical PRC1.1 proteins like KDM2B,
PCGF1, and BCOR(L1). Knockdown of PRC1.1 subunits strongly
impaired leukemic cell growth in vitro. PRC1.1 complex partners
are frequently overexpressed in human AML patients, and using
our in vivo MLL-AF9 and primary AML patient humanized niche
xenograft models, we could demonstrate that leukemia initiation
and maintenance both required the presence of a functional
PRC1.1 complex. Finally, we observed that PRC1.1 targets a
large set of active genes involved in metabolism and cell cycle
in primary AML patient cells independent of H3K27me3.
A role for PRC1.1 in leukemic transformation andmaintenance
arose from our expression data showing upregulation of various
members of the PRC1.1 complex in AML CD34+ cells versus
normal BMCD34+ cells (de Jonge et al., 2011). Therefore, we hy-
pothesize that increased PRC1.1 expression may act as an
oncogenic hit in the process of leukemogenesis. In line with
this idea, overexpression of murine KDM2B induces transforma-
tion of mouse BM cells and KDM2B knockdown conversely ab-
rogates Hoxa9/Meis1-induced leukemogenesis (He et al., 2011).
Interestingly, KDM2B was also overexpressed in human pancre-
atic ductal adenocarcinoma cells, and KDM2B collaborated with
mutant KRAS to induce pancreatic tumors in mouse models
(Tzatsos et al., 2013). Similarly, increased abundance of the
PRC1.1 complex in human leukemic cells may act as a primary
or secondary oncogenic hit.
The severe negative phenotype upon downregulation of
PRC1.1 members in primary MLL-AF9 cells is in contrast
with the milder phenotype observed upon knockdown of ca-
nonical PRC1 complex members like PCGF4 and CBX2. In
contrast, normal CB CD34+ cells critically depend on a func-
tional PRC1 complex and display strong sensitivity to CBX2
knockdown (van den Boom et al., 2013). These data suggest
that PRC1 paralog dependency in normal human hematopoiet-
ic stem/progenitor cells versus leukemic cells in AML is quite
distinct. The mild phenotype of PCGF4 knockdown resembles
the observation that MLL-AF9-induced leukemic transforma-
tion of mouse BM cells is independent of PCGF4/BMI1, and
HOXA9 may replace PCGF4/BMI1 as a repressor of the
CDKN2A locus (Smith et al., 2011). Previously, Tan and
colleagues reported that MLL-AF9-induced leukemogenesis
depends on CBX8 in a PRC1-independent manner and sug-
gested a co-activating role for CBX8 on MLL-AF9 target genes
(Tan et al., 2011). Similarly, we found that CBX8 knockdown
reduced cell proliferation and colony formation in MLL-AF9
liquid cultures and CFC analyses. In contrast to our study,
knockdown of RING1B did not affect MLL-AF9-dependent
cell growth in their model system, at least not in relatively short
in vitro assays in which cells were analyzed for 5–10 days (Tan
et al., 2011). It is currently not clear which mechanisms might
underlie these different observations, but it is possible that
PRC1 paralog dependency differs between human models
and mouse models driven by leukemic granulocyte-macro-
phage progenitors.
Although knockdown of KDM2B, PCGF1, and BCOR strongly
impaired MLL-AF9-induced leukemogenesis, we unexpectedly
observed that downregulation of RYBP, an integral part of non-
canonical PRC1 complexes, resulted in a rather mild negative
phenotype in CB MLL-AF9 cells. An explanation for this pheno-
type could be that RYBP is replaced by its homolog YAF2, in line
with previous data showing that YAF2 and RYBP can reside in
variant PRC complexes in a mutually exclusive manner (Gao
et al., 2012).
Using a ChIP-seq approach in K562 leukemic cells and pri-
mary CD34+ AML patient cells, we identified genes that are tar-
geted by PRC1.1 and/or PRC1. In line with previous studies in
mouse embryonic stem cells, we find that PRC1.1 preferentially
targets CGI-containing TSSs (Farcas et al., 2012; He et al., 2013;
Wu et al., 2013). Where these studies showed that PRC1.1 often
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Figure 5. Distinct Targeting of Non-canonical PRC1.1 and PRC1 in Primary CD34+ AML Patient Cells
(A) Venn diagrams showing overlap of genes targeted by KDM2B, H2AK119ub, and H3K27me3 in six independent AML patient samples.
(B) ChIP-seq heatmap of peaks (5 to +5 kb) targeted by PRC1.1, PRC1, or both in all analyzed AML samples.
(C) Chromosomal localization of peaks enriched for PRC1.1, PRC1, or both complexes. The average of all six AML samples is shown.
(D) Percentage of H3K4me3-enriched peaks targeted by PRC1.1, PRC1, or both complexes in all measured primary AML patient samples.
(E) Representative examples of genes targeted by PRC1.1 and/or PRC1 in two independent AMLs.
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co-represses genes together with canonical PRC1 and PRC2
complexes, we observe a large fraction of genes that is preferen-
tially targeted by PRC1.1 and enriched for H2AK119ub but
devoid of H3K27me3 (Farcas et al., 2012; He et al., 2013; Wu
et al., 2013). We do find some binding of PCGF2/4 at PRC1.1
sites suggesting that canonical PRC1 may also bind these loci,
though with lower efficiency than PRC1.1. These data suggest
that PRC1.1 can target chromatin independently of PRC2, in
line with recent data that PRC1.1 can act as an initiating complex
in Polycomb-mediated silencing (Cooper et al., 2014; Black-
ledge et al., 2014; Kalb et al., 2014). In contrast, PRC1 target
genes are strongly enriched for H3K27me3, and a category of
genes targeted by both PRC1 and PRC1.1 display an intermedi-
ate situation where H3K27me3 is found but to a lesser extent
B
010 -2010 -4010 -6010 -8010
metabolic process
chromosome organization
macromolecule metabolic process
chromatin modification
protein modification process
biosynthetic process
cell cycle
developmental process
multicell. organismal development
anatomical structure development
system development
organ development
cell differentiation
nervous system development
system development
anatomical structure development
multicell. organismal development
developmental process
organ development
nervous system development
cell differentiation
GO analysis AML 6
p-value
P
R
C
1.
1
P
R
C
1
bo
th
C
501 PB CD34+AML CD34+ 1054 1475
D
PB CD34+
2529
PRC1.1
3549
both
1294
PRC1
KDM2B
8091
H3K27me3
5129
H2AK119ub
9748
P
er
ce
nt
ag
e 
of
 in
pu
t
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
PA
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
FA
P
3L
C
D
K
N
1A
70
60
50
30
20
0
10
40
H3K27me3
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
PA
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
FA
P
3L
C
D
K
N
1A
35
25
20
15
5
0
10
30
H2AK119ub
IgG
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
PA
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
F A
P
3L
C
D
K
N
1A
25
20
15
10
5
0
H3K4me3
IgG
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
P A
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
F A
P
3L
C
D
K
N
1A
1.8
1.4
1.0
0.6
0.2
1.6
1.2
0.8
0.4
0
KDM2B
IgG
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
PA
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
FA
P
3L
C
D
K
N
1A
0.20
0.12
0.04
0.16
0.08
0
PCGF4
IgG
AML3
PRC1.1 PRC1 both
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
PA
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
FA
P
3L
C
D
K
N
1A
100
80
60
40
20
0
IgG
H3K27me3
IgG
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
PA
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
FA
P
3L
C
D
K
N
1A
30
25
20
15
5
0
10
H2AK119ub
IgG
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
PA
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
FA
P
3L
C
D
K
N
1A
20
16
12
8
4
0
H3K4me3
IgG
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
P A
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
FA
P
3L
C
D
K
N
1A
1.8
1.4
1.0
0.6
0.2
1.6
1.2
0.8
0.4
0
KDM2B
IgG
P
K
M
M
A
P
3K
6
S
E
R
G
E
F
E
P
C
2
E
R
C
C
1
G
A
LK
1
A
LO
X
15
TF
A
P
2B
TC
F2
1
N
K
X
2-
6
PA
X
7
IN
K
4A
FO
X
P
4
N
K
X
3-
1
R
A
B
23
M
FA
P
3L
C
D
K
N
1A
0.12
0.06
0.02
0.08
0.04
0
0.10
PCGF4
IgG
AML2
PRC1.1 PRC1 both
A
Figure 6. Specific PRC1.1 Targeting in AML and Normal PB CD34+ Cells
(A) ChIP-qPCR on PRC1.1, PRC1, and both target genes using antibodies directed against H3K27me3, H2AK119ub, H3K4me3, KDM2B, and PCGF4.
(B) GO analyses of gene sets targeted by PRC1.1, PRC1, or both complexes (AML6).
(C) Venn diagram showing overlap of genes targeted by KDM2B, H2AK119ub, and H3K27me3 in normal PB CD34+ cells.
(D) Overlap in non-canonical PRC1.1 targeted genes in AML CD34+ cells (we considered a gene a PRC1.1 target gene if it was found in five out of six AMLs)
compared to normal PB CD34+ cells.
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compared to exclusive PRC1 gene targets. Interestingly, Farcas
and colleagues make note of low-magnitude RING1B binding
sites in mES cells, which are lost upon either RING1B depletion
or KDM2B knockdown and only infrequently coincide with PRC2
(Farcas et al., 2012). These sites may be similar to the PRC1.1
target genes that we identified, although we observed a strong
enrichment for PRC1.1 complex members rather than weak
binding. Farcas and colleagues suggested that these genes
are targeted to make them susceptible to Polycomb-mediated
silencing. We hypothesize that in leukemic cells, PRC1.1 might
specifically regulate the activity of its target genes. In line with
this idea, PRC1.1 bound genes displayed transcriptionally active
chromatin profiles that were strongly enriched for H3K4me3,
H3K36me3 and active RNA polymerase II. Furthermore, the
expression of the PRC1.1 target gene MYC was increased
upon RING1A/B knockdown, suggesting an activating role for
the PRC1.1 complex. RING1B may play a role in recruitment
of RNA polymerase II as recently suggested by Frangini
and colleagues, who showed that RING1B, together with Aurora
B kinase, regulates active genes in resting B and T cells
(Frangini et al., 2013). Interestingly, a recent study shows that
KDM2B binding to non-methylated CGIs prevents CpG methyl-
ation at these sites (Boulard et al., 2015). Although not
addressed in our current work, PRC1.1 may prevent CGI hyper-
methylation at target genes, thereby maintaining their transcrip-
tional activity.
We compared non-canonical PRC1.1 target genes in AML
CD34+ samples with normal PB CD34+ samples, and we
observed that besides AML-specific and normal PB-specific
loci, a considerable overlap exists, suggesting that these
PRC1.1 genes are controlled by non-canonical signaling in
both normal and leukemic cells. Future studies will be aimed at
further unraveling similarities and differences between normal
and leukemic cells, but what is clear now is that PRC1.1 mostly
targeted genes involved in metabolism, whereas canonical
PRC1/2 predominantly binds classical Polycomb target genes
involved in developmental processes. Interestingly, the non-ca-
nonical RYBP-PRC1 complex was also found to target meta-
bolic genes in mES cells (Morey et al., 2013). Here, RYBP-
PRC1 targets were annotated by the presence of RING1B,
RYBP, and H2AK119ub, but not CBX7. Since RING1B and
RYBP are also PRC1.1 subunits, part of these enriched regions
may in fact be PRC1.1 target genes. In addition, in human
pancreatic ductal adenocarcinoma cells it was also found that
KDM2B targets a large group of metabolic genes independent
of EZH2 (Tzatsos et al., 2013). Furthermore, Brookes and col-
leagues previously identified a set of active PRC loci that were
enriched for metabolic genes as well (Brookes et al., 2012).
Taken together, we suggest that the non-canonical PRC1.1
complex targets a variety of active genes involved in metabolism
independently of H3K27me3.
These metabolic PRC1.1 target genes include enzymes func-
tioning in the glycolytic pathway like pyruvate kinase (PKM) and
lactate dehydrogenase (LDHA). KDM2B recently was suggested
to positively regulate the glycolytic pathway (Yu et al., 2015).
Furthermore, the Scadden lab recently demonstrated that
expression of both PKM (PKM2 splice variant) and LDHA are
essential for leukemogenesis and that loss of either gene re-
sulted in delayed leukemic onset of BCR-ABL and MLL-AF9
induced leukemias in vivo (Wang et al., 2014). We hypothesize
that deregulated expression of these glycolytic genes upon
PRC1.1 depletion contributes to the observed phenotypes in
leukemogenesis. In addition, also other cancer-related genes,
such as the cell-cycle regulatory gene MYC, were controlled
by PRC1.1.
Taken together, we propose that the non-canonical PRC1.1
complex is essential for leukemic transformation and that its tar-
geting might prove an excellent way to eradicate leukemic stem
cells, with the ultimate aim to prevent relapse of the disease. It
will be of great interest to investigate which PRC1.1-regulated
cellular pathways are essential for leukemic stem cell function
and whether pharmacological inhibition of either of these path-
ways, or PRC1.1 itself, may prove a rigid therapy in AML.
EXPERIMENTAL PROCEDURES
In Vivo Transplantations into NSG Mice
8- to 10-week-old female NSG (NOD.Cg-Prkdcscid ll2rgtm1Wjl/SzJ) mice
were purchased from the Centrale Dienst Proefdieren breeding facility within
the University Medical Center Groningen. Mouse experiments were performed
in accordance with national and institutional guidelines, and all experiments
were approved by the Institutional Animal Care and Use Committee of the Uni-
versity of Groningen Prior to transplantations, mice were sublethally irradiated
with a dose of 1.0 Gy (Rizo et al., 2010). Following irradiation, mice received
neomycin (3.5 g/l in drinking water) and soft food daily for 2 weeks. Mice
were injected intravenously with 13 105 sorted MA9/shSCR, MA9/shRING1A,
or MA9/shRING1B CB CD34+ cells. Mice were sacrificed when chimerism
levels in the PB exceeded 30% and/or when mice appeared lethargic.
ChIP
ChIP was essentially performed as described previously (Frank et al., 2001).
Briefly, K562 cells were transduced with the lentiviral GFP-fusion vectors en-
coding GFP-CBX2, PCGF1-GPF, PCGF2-GFP, PCGF4-GFP, GFP-RING1A,
or GFP-RING1B. K562 cells expressing GFP fusions at relatively low levels
were sorted and expanded and subsequently crosslinked. ChIP reactions
were performed using the following antibodies: anti-GFP (ab290, Abcam),
anti-H3K27me3 (07-449, Millipore), anti-H3K4me3 (ab8580, Abcam), anti-
H2AK119ub (D27C4, Cell Signaling Technology), anti-KDM2B (ab137547, Ab-
cam), and anti-BMI1 (AF27). ChIP efficiencies were determined by qPCR.
Additional materials and methods can be found in Supplemental Experi-
mental Procedures.
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